Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade

Abstract

Metastatic prostate cancer (PC) is incurable by androgen deprivation therapy alone, due to the presence of androgen-independent/supersensitive cells in hormone-naive PC. A 67-year-old man was diagnosed with PC (Gleason score, 5 + 4) with multiple bone metastases. He was treated by chemohormonal therapy with cisplatin and estramustine phosphate (EMP) followed by maximal androgen blockade, and showed a complete response. As of the time of writing, no clinical or prostate-specific antigen recurrence has been observed for over 15 years, despite cessation of the treatment. This is the first report to indicate a possible cure of metastatic PC by chemohormonal therapy combined with appropriate anti-tumor drugs targeted to both androgen-independent and -dependent clones before the hormone-refractory state.

Adenoviral‐mediated pHyde Gene Transfer and Cisplatin Additively Inhibit Human Prostate Cancer Growth by Enhancing Apoptosis

“…Consistently, our study showed that AdRSVpHyde and cisplatin have an additive inhibitory effect on suppression of prostate cancer cell growth both in vitro and in vivo. While our study focused on the use of cisplatin, which is commonly used as a treatment strategy for prostate cancer (either alone or combined with other agents or another therapeutic modality) [18][19][20][21][22][23][24], we also investigated anti-prostate cancer effects of another chemotherapeutic drug, docetaxel, which is equally commonused for treatment of prostate cancer [18,25]. We found that AdRSVpHyde and docetaxel have an additive inhibitory effect on growth of prostate cancer cells as well.…”

“…Like cisplatin which is commonly used as a treatment strategy for prostate cancer [18][19][20][21][22][23][24], docetaxel is another chemotherapeutic drug equally common-used for treatment of prostate cancer [18,25]. To investigate whether pHyde and docetaxel have a similar additively inhibitory effect on prostate cancer, we used AdRSV-pHyde coupled with docetaxel to examine the anticancer effects in DU145 cells.…”

Synthesis of Nanocurcumin - Alginate Conjugate and its Characterization by XRD, IR, UV-VIS Andraman Spectroscopy

“…3 However, it has been well known that the application of curcumin was limited due to its low water solubility, high degradation, and poor bioavailability. [4][5][6][7][8][9][10] For decades, several studies have been made to compensate for these disadvantages, with the development of improved drug delivery methods [11][12][13][14][15][16] . Recent researches witnessed the encouraging progress in the use of nanoscale drug delivery systems on curcumin such as loading curcumin into liposomes or nanoparticles, forming self-micro emulsifying drug delivery systems, cyclodextrin inclusions, and solid dispersions, as well as the latest reported technologies such as nano disks and nanotubes.…”

Does chemotherapy have a role before hormone-resistant disease develops?

“…Potential Long-Term Benefi ts of Chemotherapy in the Hormone-Sensitive Patient Intriguingly, there are case reports of apparent cure or long-term disease control in patients with metastatic disease treated with combined chemohormonal therapy. In one case reported by Urakami et al [10], a patient presented in 1992 with Gleason 5 + 4 adenocarcinoma of the prostate: PSA was 444 ng/mL, alkaline phosphatase was 1173 IU/L, and lymph node and multiple bone metastases were identifi ed. The patient was fi rst treated with cisplatin and EMP for 9 weeks, then underwent orchiectomy and was continued on estramustine therapy.…”